Qu Biologics publishes potentially paradigm-shifting results of their first randomized-placebo controlled trial for the treatment of Crohn’s disease


You May Also Like

NewLink Genetics to Participate in Upcoming Investor Conferences

AMES, Iowa, Aug. 29, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that ...

Stemline Therapeutics Closes $92 Million Public Offering of Common Stock

NEW YORK, Jan. 18, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a ...